Home » EMA’s CHMP Recommends Three Drugs at April Meeting
EMA’s CHMP Recommends Three Drugs at April Meeting
Drugs Submissions and Approvals
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended three medicines for approval and eight extensions at its April 23-26 meeting.
The committee endorsed a marketing authorization for Gilead’s HIV-1 treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
The CHMP recommended approval of Carmustine Obvius (carmustine) a generic drug for treatment Hodgkin’s disease, non-Hodgkin’s lymphoma and brain tumors.
It also issued a positive opinion for the pain treatment Dzuveo (sufentanil).